Company / Cash & Equivalents
Kiniksa Pharmaceuticals International, plc Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$165.6M
FY2025
5-year range
$108.0M / $183.6M
FY2021-FY2025
Trend
-9.8%
vs FY2024
Sector context
#107 of 207
Health Care
What the data says
At $166M, Kiniksa Pharmaceuticals International, plc's cash & equivalents ranks #107 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 9 years, ranging from $46M in FY2017 to $184M in FY2024.
Based on SEC 10-K filings.
$166M in FY2025 with a 5-year CAGR of +7.7%.
Improved from $108M to $166M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +10.5%
- 5-Year CAGR
- +7.7%
- 10-Year CAGR
- -
Sector benchmark
#107 of 207 in Health CareTop 52% of 207This company $165.6M Sector average $669.5M
▼
-75.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.7%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 9.8% year-over-year.
- Ranks #107 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $165.6M | -9.8% |
| FY2024 | $183.6M | +70.1% |
| FY2023 | $108.0M | -12.0% |
| FY2022 | $122.7M | +0.2% |
| FY2021 | $122.5M | +7.4% |
| FY2020 | $114.0M | +143.0% |
| FY2019 | $46.9M | -34.8% |
| FY2018 | $72.0M | +58.0% |
| FY2017 | $45.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026